(Q38742141)

6 September 2017

title

Recent Advances in Developing Antiviral Therapies for Respiratory Syncytial Virus (English)

1 reference

6 September 2017

Brian C Shook

1

1 reference

6 September 2017

Kai Lin

series ordinal

2

1 reference

6 September 2017

publication date

21 March 2017

1 reference

Topics in Current Chemistry

6 September 2017

published in

1 reference

6 September 2017

volume

375

1 reference

6 September 2017

issue

2

1 reference

6 September 2017

page(s)

40

1 reference

https://scigraph.springernature.com/pub.10.1007/s41061-017-0129-4

6 September 2017

exact match

0 references

cites work

An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

The burden of respiratory syncytial virus infection in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Respiratory syncytial virus infection in elderly and high-risk adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Mortality associated with influenza and respiratory syncytial virus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Risk of severe respiratory syncytial virus disease, identification of high risk infants and recommendations for prophylaxis with palivizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Aerosolized ribavirin: the most expensive drug for pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Multiple functional domains and complexes of the two nonstructural proteins of human respiratory syncytial virus contribute to interferon suppression and cellular location

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Nonstructural proteins of respiratory syncytial virus suppress premature apoptosis by an NF-kappaB-dependent, interferon-independent mechanism and facilitate virus growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

CX3CR1 Is Expressed in Differentiated Human Ciliated Airway Cells and Co-Localizes with Respiratory Syncytial Virus on Cilia in a G Protein-Dependent Manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Viral load drives disease in humans experimentally infected with respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Nasal quantity of respiratory syncytical virus correlates with disease severity in hospitalized infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Development of a simple, rapid, sensitive, high-throughput luciferase reporter based microneutralization test for measurement of virus neutralizing antibodies following Respiratory Syncytial Virus vaccination and infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Development of a high-throughput replicon assay for the identification of respiratory syncytial virus inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Animal models of human respiratory syncytial virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

The cotton rat model of respiratory viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Antiviral Activity of TMC353121, a Respiratory Syncytial Virus (RSV) Fusion Inhibitor, in a Non-Human Primate Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Molecular Basis for the Selective Inhibition of Respiratory Syncytial Virus RNA Polymerase by 2'-Fluoro-4'-Chloromethyl-Cytidine Triphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Phenotypic analysis of local cellular responses in calves infected with bovine respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Perinatal lamb model of respiratory syncytial virus (RSV) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Oral GS-5806 activity in a respiratory syncytial virus challenge study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Structure-guided design of small-molecule therapeutics against RSV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: identification of BTA9881 as a preclinical candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

The discovery of 1,2,3,9b-tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Fundamental structure-activity relationships associated with a new structural class of respiratory syncytial virus inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Respiratory syncytial virus inhibitors. Part 2: Benzimidazol-2-one derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Respiratory syncytial virus fusion inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Cold virus fusion or stopping fusion cold--inhibitors of the human respiratory syncytial virus F protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Inhibition of Respiratory Syncytial Virus Fusion by the Small Molecule VP-14637 via Specific Interactions with F Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Discovery of Piperazinylquinoline Derivatives as Novel Respiratory Syncytial Virus Fusion Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

1,4-Benzodiazepines as inhibitors of respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

1,4-benzodiazepines as inhibitors of respiratory syncytial virus. The identification of a clinical candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

RSV604, a novel inhibitor of respiratory syncytial virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Mechanism of action for respiratory syncytial virus inhibitor RSV604.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

A Druggable Pocket at the Nucleocapsid/Phosphoprotein Interaction Site of Human Respiratory Syncytial Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

New antiviral approaches for respiratory syncytial virus and other mononegaviruses: Inhibiting the RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Characterization of a respiratory syncytial virus L protein inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Discovery of β-D-2'-deoxy-2'-α-fluoro-4'-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

The respiratory syncytial virus M2-1 protein forms tetramers and interacts with RNA and P in a competitive manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

The Cys(3)-His(1) motif of the respiratory syncytial virus M2-1 protein is essential for protein function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Inactivation of respiratory syncytial virus by zinc finger reactive compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Crystal structure of the essential transcription antiterminator M2-1 protein of human respiratory syncytial virus and implications of its phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

In silico structure-based design and synthesis of novel anti-RSV compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Targeting human respiratory syncytial virus transcription anti-termination factor M2-1 to inhibit in vivo viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Optimization of potent and selective quinazolinediones: inhibitors of respiratory syncytial virus that block RNA-dependent RNA-polymerase complex activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Benzimidazole analogs inhibit respiratory syncytial virus G protein function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Characterization of novel respiratory syncytial virus inhibitors identified by high throughput screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

The efficacy of intranasal interferon alpha-2a in respiratory syncytial virus infection in volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Respiratory syncytial virus load predicts disease severity in previously healthy infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Comparison of a real-time reverse transcriptase PCR assay and a culture technique for quantitative assessment of viral load in children naturally infected with respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS41061-017-0129-4

10.1007/S41061-017-0129-4

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference